Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Novo Nordisk and Eli Lilly, two pharmaceutical titans with decades of competitive history, are positioning themselves for a critical battle over the emerging oral GLP-1 receptor agonist market as Medicare coverage determinations loom. The Danish manufacturer has developed rybelsus, an oral formulation of semaglutide, while the American company is advancing tirzepatide pills alongside its established injectable dual GLP-1/GIP receptor agonist. Both firms recognize that securing Medicare coverage represents a watershed moment for this therapeutic category, potentially unlocking access to roughly 45 million American seniors and establishing market dominance in what analysts project could become a multi-billion-dollar segment. The coverage decisions from the Centers for Medicare and Medicaid Services, expected in coming months, will determine which company can offer the most accessible entry point to oral weight-loss and diabetes medications for the Medicare population, a demographic that has been largely excluded from the current injectable GLP-1 boom driven by branded alternatives like Ozempic and Wegovy.

The rivalry between Novo Nordisk and Eli Lilly extends back decades through their competition in insulin and diabetes care, but the GLP-1 market has fundamentally reshaped their strategic positioning. Novo Nordisk enjoyed early dominance with semaglutide's injectable forms, becoming a household name following the blockbuster success of Wegovy for weight management and Ozempic for type 2 diabetes. However, Eli Lilly's tirzepatide has emerged as a formidable challenger, demonstrating superior weight loss results in clinical trials and capturing significant market share despite entering later than Novo's offerings. The transition to oral formulations carries immense business implications because pills eliminate the injection barrier that has restricted adoption among needle-averse patients while potentially reducing manufacturing and distribution complexity. For Medicare specifically, the oral route addresses a critical gap in access, as older adults often face dexterity challenges or cognitive concerns that make self-administered injections problematic. This moment represents not merely a product innovation dispute but a fundamental reshaping of how these two competitors will vie for dominance among seniors, the fastest-growing demographic segment seeking weight management solutions and the population most dependent on Medicare coverage determinations to guide their treatment choices.

Novo Nordisk's rybelsus delivers semaglutide through an oral tablet formulation that utilizes absorption-enhancing technology to overcome the peptide's natural degradation in the gastrointestinal tract. The company has already demonstrated efficacy and safety data suggesting that rybelsus achieves meaningful weight reduction and glycemic control comparable to injectable semaglutide, positioning it as a direct pharmaceutical equivalent in pill form. Eli Lilly's oral tirzepatide program represents similarly advanced development, with the company filing for regulatory approval based on robust clinical trial data showing this formulation maintains the dual receptor agonism that has distinguished tirzepatide from monotherapy GLP-1 approaches. Both manufacturers face the critical challenge of proving to Medicare decision-makers that their oral formulations deliver sufficient clinical benefit to justify coverage alongside existing therapies, particularly given the established success and lower relative costs of certain injectable alternatives. The coverage determination process will examine not only efficacy metrics but also real-world effectiveness in the Medicare population, adherence patterns among seniors, and cost-effectiveness ratios that Medicare uses to evaluate whether therapies represent appropriate value expenditures for beneficiaries.

The business implications of Medicare coverage for oral GLP-1 agents extend far beyond these two manufacturers, reshaping the entire competitive landscape of the obesity and diabetes treatment markets. Medicare represents the single largest purchaser of pharmaceuticals in the United States, with coverage decisions directly influencing pricing power, market access, and formulary placement across the broader healthcare system. If Medicare approves oral semaglutide or tirzepatide coverage, insurers and pharmacy benefit managers will face pressure to incorporate these agents into their formularies, potentially creating preferred agent status that could redirect patient volume away from current market leaders or restrict access to competing injectables. For seniors specifically, oral access removes a significant psychological and practical barrier that has prevented adoption, potentially creating a new wave of medication initiation among the Medicare population who have watched obesity and weight-related metabolic disease proceed unaddressed because of injection concerns or inadequate coverage of existing agents. This expansion represents a substantial financial opportunity for whichever company secures preferred positioning, as the Medicare population utilizes medications at rates exceeding younger demographics, and chronic weight management typically requires long-term continuous therapy rather than episodic treatment.

The competitive positioning between Novo Nordisk and Eli Lilly in oral GLP-1 development reflects a broader industry shift toward reducing friction in medication administration while intensifying competition among manufacturers already established in the GLP-1 space. Both companies recognize that the injectable GLP-1 market, despite explosive growth, has matured sufficiently that differentiation now depends on convenience, accessibility, and patient preference rather than pure efficacy superiority, as both semaglutide and tirzepatide have demonstrated compelling clinical benefits. The oral formulation competition mirrors similar transitions in other therapeutic categories where market leaders have defended positions by expanding delivery options, whether through extended-release formulations, combination therapies, or alternative administration routes. The emergence of tirzepatide as a serious competitive threat to Novo's historical dominance demonstrates that market leadership in biologics and specialty pharmaceuticals remains contestable, particularly when challengers offer clinically meaningful advantages or improved delivery mechanisms. The Medicare coverage decision becomes a pivotal moment where regulatory and purchasing decisions interact to reshape competitive dynamics, potentially elevating one manufacturer's oral offering as the standard while relegating alternatives to secondary positions.

Investors and healthcare stakeholders should closely monitor the Centers for Medicare and Medicaid Services coverage decisions expected through 2024 and early 2025, as these determinations will establish the framework for oral GLP-1 adoption among seniors and influence negotiated pricing for both manufacturers. Novo Nordisk's quarterly earnings reports and pipeline communications regarding rybelsus market performance in the Medicare population will signal whether early adoption justifies the company's continued investment in oral semaglutide expansion and formulary negotiation strategies. Eli Lilly's oral tirzepatide approval timeline and subsequent Medicare coverage determinations will similarly indicate whether the company's clinical superiority claims translate into real-world market penetration advantages among seniors, potentially reshaping the competitive trajectory in GLP-1 therapeutics more broadly. The broader pharmaceutical industry should recognize this competition as emblematic of how established market leaders must continually innovate and adapt distribution strategies to maintain position, even when facing well-resourced competitors offering clinically comparable alternatives. Healthcare systems and pharmacy benefit managers must prepare now for formulary decisions that will follow Medicare coverage approvals, as the period between regulatory authorization and coverage determination represents a critical window where manufacturer positioning, rebate negotiations, and preferred agent status will be determined. The outcome of this competitive engagement will reverberate through the Medicare program for years, affecting treatment patterns, patient outcomes, and company valuations in ways that justify the substantial development investments both manufacturers have deployed in oral GLP-1 formulation programs.